Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cognitive function in schizophrenia

D R Weinberger1, B Gallhofer

  • 1Clinical Brain Disorders Branch, National Institute of Mental Health, Neurosciences Center at Saint Elizabeths, Washington, DC 20032, USA.

International Clinical Psychopharmacology
|November 14, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic vulnerability to DUSP22 promoter hypermethylation is involved in the relation between in utero famine exposure and schizophrenia.

NPJ schizophrenia·2018
Same author

GWAS meta-analysis reveals novel loci and genetic correlates for general cognitive function: a report from the COGENT consortium.

Molecular psychiatry·2017
Same author

Longitudinal analyses of the DNA methylome in deployed military servicemen identify susceptibility loci for post-traumatic stress disorder.

Molecular psychiatry·2017
Same author

GAD1 alternative transcripts and DNA methylation in human prefrontal cortex and hippocampus in brain development, schizophrenia.

Molecular psychiatry·2017
Same author

Investigating the neuroimmunogenic architecture of schizophrenia.

Molecular psychiatry·2017
Same author

Altered expression of histamine signaling genes in autism spectrum disorder.

Translational psychiatry·2017
Same journal

Critical reassessment of manic and psychotic episodes related to levetiracetam: a systematic review of published case reports.

International clinical psychopharmacology·2026
Same journal

Expanding the horizon of brexpiprazole augmentation in treatment-resistant disorders: from obsessive-compulsive disorder to adolescent bipolar disorder.

International clinical psychopharmacology·2026
Same journal

Acceptability-adjusted speed in psychotic agitation: interpreting pro re nata antipsychotic data in real-world care (commentary on Hatta et al.).

International clinical psychopharmacology·2026
Same journal

Antipsychotics in clinical practice: agitation, polypharmacy, and treatment resistance.

International clinical psychopharmacology·2026
Same journal

Methylphenidate treatment in adults with comorbid attention-deficit/hyperactivity disorder and borderline personality disorder: a prospective longitudinal study.

International clinical psychopharmacology·2026
Same journal

Association between anxious depression and clinical outcomes in subjects with treatment-resistant depression: a comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment-resistant depression (ASCERTAIN-TRD).

International clinical psychopharmacology·2026
See all related articles

Cognitive dysfunction is a core feature of schizophrenia, impacting information processing and long-term disability. Antipsychotics targeting 5-hydroxytryptamine (5-HT)2A receptors may improve cognitive function more than dopamine (D)2 blockers.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Cognitive dysfunction in schizophrenia is a core, enduring feature, not just a secondary effect of psychosis.
  • Deficits in information manipulation and working executive memory are significant and predict long-term disability.
  • Neuroimaging suggests prefrontal activity is crucial for cognitive functions affected in schizophrenia.

Purpose of the Study:

  • To review the role of cognitive dysfunction in schizophrenia.
  • To explore the impact of different antipsychotic drug mechanisms on cognitive function.
  • To assess the potential of 5-HT2A-blocking antipsychotics for improving cognitive outcomes.

Main Methods:

  • Review of existing literature on cognitive deficits in schizophrenia.

Related Experiment Videos

  • Analysis of neuroimaging and functional studies related to prefrontal activity.
  • Comparison of cognitive effects of 5-HT2A-blocking vs. D2-blocking antipsychotic drugs.

    • Main Results:

    • Cognitive deficits are stable and significantly impact daily functioning in schizophrenia.
    • Prefrontal cortex activity is essential for cognitive processes impaired in schizophrenia.
    • Antipsychotics with 5-HT2A-blocking activity demonstrate superior cognitive benefits compared to D2-blocking agents.

    Conclusions:

    • Cognitive dysfunction is a primary target for schizophrenia treatment.
    • Antipsychotic medications with 5-HT2A receptor blockade show promise for enhancing cognitive function.
    • Improved cognitive function may lead to better life role functioning for patients with schizophrenia.